|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 498/18 | (2006.01) |
| C07D 498/18 | (2013.01) | ||
| A61K 31/439 | (2006.01) | ||
| C07B2200/13 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/4162 | (2013.01) |
| (11) | Number of the document | 3798222 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20202336.2 |
| Date of filing the European patent application | 2016-07-27 | |
| (97) | Date of publication of the European application | 2021-03-31 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-22 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201562199418 P | 2015-07-31 | US | |
| 201662352349 P | 2016-06-20 | US |
| (72) |
BIRCH, Melissa J. , GB
PENCHEVA, Klimentina Dimitrova , GB
McALLISTER, Stephen Mark , GB
ROWLAND, Martin Gregory , GB
SMALES, Ian Leonard , GB
|
| (73) |
Pfizer Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | CRYSTALLINE FORM OF LORLATINIB FREE BASE |
| CRYSTALLINE FORM OF LORLATINIB FREE BASE |